2
Clinical Trials associated with Insulin degludec/Insulin aspart (Dongguan HEC Biopharmaceutical)A Multi-center, Randomized, Open, Phase III Study of Insulin Degludec/Insulin Aspart Biosimilar (22011) Compared Efficacy and Safety With Insulin Degludec/Insulin Aspart(Ryzodeg) in Chinese Subjects With Type 2 Diabetes
The purpose of this study is to see if Insulin Degludec/Insulin Aspart (22011) compared to Insulin Degludec/Insulin Aspart (Ryzodeg) is similar in safety and effect in participants with type 2 diabetes (T2D).
一项在健康受试者中比较德谷门冬双胰岛素注射液(22011)与德谷门冬双胰岛素注射液(诺和佳®)药代动力学和药效学特征的I期临床研究
[Translation] A Phase I clinical study comparing the pharmacokinetic and pharmacodynamic characteristics of degludec and insulin aspart injection (22011) and degludec and insulin aspart injection (Truoga®) in healthy subjects
以诺和诺德公司研发的德谷门冬双胰岛素注射液(诺和佳®)为对照药品,评价单剂量皮下注射东莞市东阳光生物药研发有限公司提供的德谷门冬双胰岛素注射液(22011)在健康受试者中的药代动力学(PK)和药效学(PD)特征,进而评价德谷门冬双胰岛素注射液(22011)和诺和佳®的生物等效性
[Translation] To evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of a single subcutaneous injection of insulin degludec (22011) provided by Dongguan Sunshine Biopharmaceuticals R&D Co., Ltd. in healthy subjects, using insulin degludec (22011) developed by Novo Nordisk as the control drug, and then to evaluate the bioequivalence of insulin degludec (22011) and insulin degludec (22011).
100 Clinical Results associated with Insulin degludec/Insulin aspart (Dongguan HEC Biopharmaceutical)
100 Translational Medicine associated with Insulin degludec/Insulin aspart (Dongguan HEC Biopharmaceutical)
100 Patents (Medical) associated with Insulin degludec/Insulin aspart (Dongguan HEC Biopharmaceutical)
100 Deals associated with Insulin degludec/Insulin aspart (Dongguan HEC Biopharmaceutical)